Skip to content
The Peptide Effect
Comparison

Hexarelin vs GHRP-6

Hexarelin and GHRP-6 are both growth hormone releasing peptides (GHRPs) that stimulate GH secretion through the ghrelin receptor (GHS-R1a), but they differ significantly in potency, sustainability, and side effect profiles. Hexarelin produces the strongest acute GH release of any GHRP — up to 2–3× the peak GH of GHRP-6 — but undergoes rapid desensitization (tachyphylaxis) within 2–4 weeks of continuous use, making it impractical for long-term protocols. GHRP-6 delivers a more moderate but sustainable GH release without significant desensitization, though it strongly stimulates appetite via ghrelin mimicry. Both elevate cortisol and prolactin to varying degrees.

Side-by-side comparison diagram of Hexarelin and GHRP-6 mechanisms of action
Conceptual comparison — not to scale

Head-to-Head Comparison

CriteriaHexarelinGHRP-6
Primary mechanismPotent ghrelin receptor (GHS-R1a) agonist — strongest acute GH release of all GHRPsGhrelin receptor (GHS-R1a) agonist — moderate GH release with strong ghrelin-like effects
GH release potencyHighest of all GHRPs — peak GH levels 2–3× higher than GHRP-6Moderate — reliable GH pulse but lower peak than hexarelin
Desensitization (tachyphylaxis)Rapid — significant blunting of GH response within 2–4 weeks of continuous useMinimal — GH response remains consistent with long-term use
Typical dosage100–200 mcg subcutaneous, 2–3× daily100–200 mcg subcutaneous, 2–3× daily
Effect on appetiteMild appetite increase — less ghrelin-like appetite stimulation than GHRP-6Strong appetite stimulation — intense hunger within 20 minutes of injection (ghrelin mimicry)
Cortisol elevationModerate — more cortisol elevation than ipamorelin, comparable to GHRP-6Moderate — notable cortisol increase, especially at higher doses
Prolactin elevationModerate — dose-dependent prolactin increaseModerate — similar prolactin elevation to hexarelin
Cardioprotective effectsYes — unique among GHRPs, hexarelin has demonstrated cardioprotective properties independent of GH release (CD36 receptor binding)Minimal — no significant cardioprotective effects demonstrated independent of GH
Best use patternShort-term bursts (2–4 weeks on, 2–4 weeks off) to avoid desensitizationContinuous long-term use possible without significant loss of efficacy
Suitability for bulkingModerate — potent GH burst but cycling requirement limits sustained anabolic benefitExcellent — strong appetite stimulation plus sustained GH release supports caloric surplus and growth
Suitability for cuttingLimited — must cycle on/off, reducing consistencyPoor — appetite stimulation counterproductive during caloric restriction
Approximate monthly cost$40–$90 (research grade)$30–$70 (research grade)

When to Choose Each

Choose Hexarelin

Short-term maximum GH release, cardiac protection research, pulsatile GH protocols with cycling, users who do not want strong appetite stimulation

Choose GHRP-6

Long-term sustained GH elevation, bulking phases where appetite stimulation is welcome, hardgainers needing to eat more, cost-effective GH peptide protocols

Verdict

GHRP-6 is the more practical choice for sustained GH elevation — its consistent efficacy without desensitization makes it suitable for longer protocols, and its strong appetite stimulation is a benefit for hardgainers or during bulking phases. Hexarelin is better reserved for short-term protocols where maximum acute GH release is desired, or for its unique cardioprotective properties via CD36 receptor activation. However, for most users seeking a clean, long-term GH peptide without appetite disruption or cortisol/prolactin concerns, ipamorelin remains superior to both hexarelin and GHRP-6.

References

  1. Hexarelin, a synthetic growth hormone-releasing peptide, cardioprotective effects and receptor binding (2000) — PubMed
  2. Growth hormone releasing peptides: clinical and basic aspects (1999) — PubMed
  3. Desensitization of growth hormone responses to GHRP-6 and hexarelin in healthy volunteers (1997) — PubMed
  4. GHRP-6 stimulates GH secretion in a dose-dependent and reproducible manner (1995) — PubMed
  5. Cardioprotective effects of hexarelin in a rat model of ischemia-reperfusion injury via CD36 receptor (2003) — PubMed

Frequently Asked Questions

Why does hexarelin cause desensitization but GHRP-6 does not?
Hexarelin is an extremely potent agonist at the GHS-R1a receptor, causing strong receptor internalization and downregulation with repeated high-dose stimulation. The pituitary somatotroph cells reduce the number of surface receptors in response to continuous intense activation. GHRP-6 produces a more moderate stimulus that allows receptor recycling and upregulation to keep pace with demand. This is similar to how high-dose opioids cause faster tolerance than lower doses — potency drives desensitization speed.
Can I prevent hexarelin desensitization by cycling?
Yes, cycling is the standard approach for hexarelin. A common protocol is 2–4 weeks on followed by 2–4 weeks off to allow GHS-R1a receptor resensitization. Some users alternate hexarelin with a milder GHRP (like ipamorelin or GHRP-2) during the off-cycle to maintain some GH elevation without continued receptor downregulation. Receptor recovery typically occurs within 1–2 weeks of cessation.
How strong is GHRP-6 appetite stimulation?
GHRP-6 appetite stimulation is intense and rapid — most users report strong hunger within 15–30 minutes of injection, lasting 30–60 minutes. This is due to its strong ghrelin-mimetic activity. The hunger can be overwhelming for some users, particularly during cutting phases. Taking GHRP-6 before a planned meal leverages this effect, while users who find it disruptive may prefer GHRP-2 (moderate appetite) or ipamorelin (minimal appetite effect).
What are the cardioprotective effects of hexarelin?
Hexarelin binds the CD36 scavenger receptor on cardiac cells independently of the GHS-R1a (ghrelin) receptor. This activates cardioprotective signaling pathways that reduce ischemia-reperfusion injury, decrease cardiac fibrosis, and improve cardiac function after myocardial infarction in animal models. These effects occur at doses lower than those needed for GH release and persist even when GH response is desensitized, suggesting a distinct mechanism. This makes hexarelin unique among GHRPs for cardiac applications.
Can hexarelin or GHRP-6 be stacked with a GHRH analog for better results?
Yes, combining a GHRP (hexarelin or GHRP-6) with a GHRH analog (CJC-1295 no-DAC or sermorelin) is a well-documented approach for amplifying growth hormone release. Research indicates the GHRH plus GHRP combination produces a synergistic GH pulse that may be 3 to 5 times greater than either peptide alone, since they activate different receptor pathways. For hexarelin, the cycling requirement still applies even when stacked. For GHRP-6, the appetite stimulation remains a factor to consider. Consulting a healthcare provider about appropriate stacking protocols and dosing is recommended.

Explore next

More comparisons